Research comparison
Tirzepatide vs Retatrutide
Tirzepatide and retatrutide are studied as the next steps in metabolic-hormone receptor research: each engages more receptors than a single-target GLP-1 analogue. The distinction between them is simply how many receptors each activates. This page compares them on objective receptor pharmacology only — it makes no human efficacy or weight claims, and describes research findings, not outcomes.
Side by side
| Tirzepatide | Retatrutide | |
|---|---|---|
| Receptor targets | GIP + GLP-1 (dual agonist) | GIP + GLP-1 + glucagon (triple agonist) |
| Receptor targets engaged | Two | Three |
| Added target vs the other | — | Adds glucagon-receptor agonism |
| Research class | Dual incretin agonist (GIP + GLP-1) | Triple hormone-receptor agonist (GIP + GLP-1 + glucagon) |
How they differ in research
A first-generation GLP-1 analogue engages one receptor. Tirzepatide engages two — the GIP and GLP-1 receptors — which is why it is described as a dual incretin agonist.
Retatrutide adds a third: the glucagon receptor, on top of GIP and GLP-1. That triple-agonist profile is the single objective difference between the two, and it is the focus of the research interest around retatrutide.
Because these are research compounds, the meaningful comparison is receptor pharmacology — how many and which receptors each engages — not any downstream human outcome, which is not something a reseller can or should claim.
Which suits which research question
The choice is defined by the research question: a dual GIP/GLP-1 model points to tirzepatide, a triple GIP/GLP-1/glucagon model points to retatrutide. Both are supplied as lyophilised research compounds for in-vitro laboratory use only, with no implication of human therapeutic use.
Frequently asked questions
What is the difference between tirzepatide and retatrutide?
The number of incretin receptors each engages. Tirzepatide is a dual GIP/GLP-1 receptor agonist; retatrutide is a triple GIP/GLP-1/glucagon receptor agonist. The added glucagon-receptor agonism is the defining difference.
Is retatrutide just a stronger tirzepatide?
They are different research compounds, not stronger-versus-weaker versions of one molecule. Retatrutide engages a third receptor (glucagon) that tirzepatide does not. Both are supplied for laboratory research use only.
Are the products on this page approved medicines?
No. CertaPeptides supplies tirzepatide and retatrutide strictly as laboratory research compounds, not as approved medicinal products, and they are not for human or animal consumption. A molecule may be separately authorised as a medicine by a regulator in some regions, but that authorisation does not apply to material supplied for research use — and CertaPeptides makes no medical, therapeutic, or efficacy claims.
This comparison describes objective compound pharmacology reported in the research literature. It is not medical guidance and makes no human efficacy, dosing, or therapeutic claims. All products are supplied by CertaPeptides (CERTALAB S.R.L.), a reseller, for laboratory research use only — not for human or animal consumption.